$TP

Ticketplus priced its Nasdaq debut at $8 a share, a $15 million raise on just 1.875 million shares

Ticketplus Ltd. (TP) priced its Nasdaq IPO at $8 per share, raising about $15 million by selling 1.875 million shares, according to the IPO pricing details. The offering is led by Roth Capital Partners with Bancroft Capital and MDB Capital, marking the company’s Nasdaq debut.

Original reporting
Published Aug 7, 2026, 9:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 10:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Ticketplus priced its Nasdaq debut at $8 a share, a $15 million raise on just 1.875 million shares — source image
Decision brief

The 30-second read

$TPNeutralMed
01

Why it matters

For traders, the key actionable input is the $8 offer price and the small 1.875 million share float, which typically increases volatility and order-book sensitivity on the first session.

02

Market read

This is a fresh, time-sensitive IPO pricing disclosure for a micro-cap, useful for positioning around first-day liquidity and volatility.

03

What to watch

No details on lockup expirations, underwriter allocation, or investor demand; those can dominate post-pricing performance.

Relevance 8/10Novelty 8/10Timing: IPO priced for Nasdaq debut today (4:00pm ET)

Background

The piece reports IPO pricing mechanics for Ticketplus’s Nasdaq debut.

Company-level read

Ticker impact

$TPNeutralMedium confidence
Context

Ticketplus priced its Nasdaq debut at $8, raising $15 million on 1.875 million shares, signaling micro-cap liquidity and day-one volatility risk.

Expected impact

Likely high first-day volatility; direction uncertain from the article alone.

Evidence & confidence

The article discloses the offer price, gross raise, and share count, but provides no demand/valuation or lockup details to infer directional bias.

Market effects

Adds a new live-event ticketing listing, but the article provides no broader sector signal beyond micro-cap IPO dynamics.

Primarily US Nasdaq micro-cap flow; limited spillover implied.

Low, as the disclosure is company-specific IPO mechanics.

Counterpoint

Tiny float can also mean faster mean reversion if initial trading is driven by mechanical IPO flows rather than fundamentals.

Key entities

  • Ticketplus Ltd.

    Priced its Nasdaq debut at $8 and raised $15 million on 1.875 million shares.

  • Roth Capital Partners

    Led the deal, alongside Bancroft Capital and MDB Capital.

  • Nasdaq

    Exchange where the company is debuting.

Related articles

$TPMedAI 8/10

Air France-KLM, Lufthansa Group submit binding bids for TAP

Air France-KLM and Lufthansa Group submitted binding bids to buy 44.9% to 49.9% of TAP Air Portugal from Portugal’s state holding Parpública, without disclosing bid values. Both said they would preserve Lisbon as a hub and expand connectivity, including transatlantic routes. Air France-KLM cited MRO investment plans supported by Delta Air Lines; Lufthansa said TAP is already in Star Alliance and Lisbon would focus on South America.

$SECZMed

Securitize Lists on NYSE and Tokenizes Its Own Stock on Day 1

Securitize (SECZ) began trading on the NYSE at $12.45, closing at $12.30. It also tokenized its stock on Solana and Avalanche, with $295M in tokenized shares at launch. The company aims to tokenize IPO allocations for crypto investors, targeting transactions within 3-6 months. Securitize reported $3.4B in tokenized assets and $19.5M in Q1 2026 revenue, up 39% YoY.

$SWMRHigh

Why SWMR Stock Soared Over 500% In Nasdaq Debut Today

Swarmer, Inc. (SWMR) shares surged 520% in its Nasdaq debut, closing at $31 after pricing its IPO at $5 per share, raising $15 million. The company, which develops drone software, plans to use proceeds for operations and expansion. Revenue was $309,920 in 2025, with a net loss of $8.5 million. CEO Alex Fink highlighted global demand driven by conflicts and the need for battlefield automation.

$ODTXHighAI 8/10

Odyssey Therapeutics Hits $900M Valuation In Nasdaq Debut, Stock Climbs 13% Before Diving Lower

Odyssey Therapeutics (ODTX) debuted on Nasdaq at $20, raising $279M via an upsized offering. Shares initially climbed 13% but later fell 10% to $16. The company also raised $25M in a private placement, totaling $304M. Proceeds will fund drug development, including OD-001 for ulcerative colitis and Crohn's disease. The company reported net losses of $148.6M in 2025 and $129.3M in 2024, with $175.7M in cash as of March 2026.

$OWLMedAI 8/10

Blue Owl Plans Data Center REIT IPO with AI Boom

Blue Owl Capital plans to create a data center REIT and take it public, seeding it with $6.5B of its own assets. The company aims to raise funds through an IPO and additional share sales to expand its portfolio. Blue Owl's shares rose 1.2% on the news, despite a 21% decline this year. Global data center expenditure is projected to reach $1.2T by 2028, according to Bloomberg Intelligence.